An LC–MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent. (June 2017)

• Record Type: Journal Article
• Authors: Parker, Suzanne L; Guerra Valero, Yarmarly C; Ordóñez Mejia, Jenny L; Roger, Claire; Lipman, Jeffrey; Roberts, Jason A; Wallis, Steven C
• Is Part Of: Bioanalysis. Volume 9:Number 12(2017)
• Page Start: 911
• Page End: 924
• Publication Date: 2017-06
• Subjects: dialysis -- mass spectrometry -- pharmacodynamics -- pharmacokinetic; Drugs -- Analysis -- Periodicals; 615.19005
• DOI: 10.4155/bio-2017-0019
• Languages: English
• ISSNs: 1757-6180

Abstract

Aim: Critical illness and medical interventions, such as renal replacement therapy, can cause changes to vancomycin pharmacokinetics and lead to suboptimal dosing. To comprehensively characterize vancomycin pharmacokinetic a method must measure vancomycin in a range of clinical matrices.Results: A LC–MS/MS method was developed using hydrophilic interaction liquid chromatography and microsample volumes, where possible. For all matrices, the linear concentration range was 1–100 μg/ml, interassay accuracy and precision was within 15%, and recovery above 80%. No matrix effects were observed. Calibration equivalence may be applied for some matrix combinations.Conclusion: A method for the analysis of vancomycin in plasma (total, unbound), urine and renal replacement therapy effluent, suitable for use in any patient pharmacokinetic study, has been developed and validated.